Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Mole101on Mar 14, 2021 10:32pm
125 Views
Post# 32796379

RE:RE:RE:Why Is Algernon Getting Slow Rolled... And The Jokes On Who?

RE:RE:RE:Why Is Algernon Getting Slow Rolled... And The Jokes On Who?

Arbourmark .. I notice you're invested on ATE too. Management behaviour was question last year about this time when they came up with PPs after great data and shareholders felt they were taking advantage of. That feeling is gone and expectations are high a year later .
 AGN is in a better position and We need to wait for results . This past year has been a tough one for research companies and harder to find subjects willing to join the studies. Two weeks and we will have a clear view of we're we stand, all this negative discussions and misleading by Algernon/jh /tanner are in my view suspicious if you actually have $$ on the line ,., don't let your shares go before the finish line 
https://clinicaltrials.gov/ct2/history/NCT04318704?V_5=View#StudyPageTop

quote=Arbourmark]Hi Bithorse,

I agree with you 100%, as mentioned previously I participated in one of the bought deals. I lost faith and sold my shares but kept my warrants as they are not free trading.

I also found it odd that they could not find enough chronic cough patients, why they would start in South Korea first for a Covid phase 2, when that country was way ahead of any other country curbing the spread of the virus.

Than out of left field they are starting study on DMT yet they have pending data on Covid-19 phase 2???? Are they suggesting results will not warrant phase 3???

Regardless my warrants will either expire or we will all get shocked with great Covid-19 results.

On a side note your writing style and font choice which is extremely hard to read is very similar to another poster Algernon, who has been absent for a long time![/quote]
 

<< Previous
Bullboard Posts
Next >>